Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, and Orient cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Jakafi is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDE?

The EDE named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDE review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any UAE-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. MOHAP, DHA, DOH, or Sharjah Health Authority verifies the active license; the EDE application records both the prescribing physician and the dispensing facility.

Can I receive Jakafi at home?

The dispensing facility must be UAE-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 14,500 to 17,000 per month. Delivered quote within 24h.Get my quote

Jakafi access in the UAE: the EDE named-patient pathway

How patients in the United Arab Emirates legally obtain Jakafi (ruxolitinib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in the UAE access Jakafi (ruxolitinib) for intermediate or high-risk myelofibrosis, polycythaemia vera with inadequate response to or intolerance of hydroxyurea, and steroid-refractory acute or chronic graft-versus-host disease under the FDA label through the EDE named-patient pathway, an Emirates Drug Establishment-administered mechanism that allows a UAE-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in AED.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Jakafi reaches patients in the UAE

Jakafi (ruxolitinib, oral JAK1 and JAK2 inhibitor, FDA-approved 2011 for intermediate or high-risk myelofibrosis, 2014 for polycythaemia vera with inadequate response to or intolerance of hydroxyurea, 2019 for steroid-refractory acute graft-versus-host disease, 2021 for steroid-refractory chronic GVHD in patients 12 years and older; marketed in ex-US markets as Jakavi by Novartis) is registered with MOHAP through Novartis UAE for selected indications; check current status at mohap.gov.ae/en/services. Where the prescribed dose strength, indication, or paediatric cGVHD dosing is not locally stocked or where supply gaps occur, UAE residents access ruxolitinib via the EDE Permit to Import Medicines for Personal Use, the service transferred from MOHAP to EDE on 29 December 2025 per mohap.gov.ae/en/mte. Hospital-led institutional imports run through the same EDE framework with the treating BMT institution as importer-of-record. The legal basis is Federal Law No. 8 of 2019. The Jakafi-specific clinical justification must document the indication-specific criteria: for MF, DIPSS or DIPSS-plus risk score and platelet-based starting dose; for PV, intolerance or inadequate response to hydroxyurea per the FDA label; for steroid-refractory acute or chronic GVHD, the steroid-refractoriness definition and prior systemic therapy lines. CBC and serum-creatinine surveillance schedule per the FDA label and the prescribing haematology and BMT team's UAE-licensure status are required.

Where Jakafi is dispensed in the UAE

Jakafi is an oral chronic therapy administered in haematology and BMT settings with serial CBC and surveillance for cytopenias, infections, and the JAK-inhibitor-class risks. UAE tertiary haematology and BMT nodes include Cleveland Clinic Abu Dhabi (CCAD) Cancer Center, BMT, and Cellular Therapies in Abu Dhabi at clevelandclinicabudhabi.ae/cancercenter; Sheikh Shakhbout Medical City (SSMC) Haematology Service in Abu Dhabi; Tawam Hospital (SEHA, affiliated with Johns Hopkins Medicine) Oncology and Haematology in Al Ain at seha.ae; Burjeel Medical City Oncology Center of Excellence Haematology in Abu Dhabi; American Hospital Dubai Haematology and Oncology; Mediclinic City Hospital Department of Haematology in Dubai; and King's College Hospital London Dubai Haematology. CCAD, SSMC, and Tawam publish departmental chairs and run BMT services with active steroid-refractory GVHD case load where ruxolitinib is the FDA-label standard. The Myeloproliferative Neoplasm clinical workflow (JAK2 V617F, CALR, or MPL mutation testing, DIPSS-plus risk stratification) is supported at all three SEHA-network and CCAD tertiary sites.

What Jakafi costs in the UAE

The US reference WAC for Jakafi is approximately USD 15,000 to USD 17,000 per 30-day supply at the 20 mg twice-daily standard MF dose per Incyte and Novartis (ex-US) disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual WAC at maintenance dose runs USD 180,000 to USD 200,000. Novartis UAE distributes ruxolitinib (Jakavi brand for ex-US markets) for the registered indications; AED pricing through MOHAP and EDE pricing services for institutional procurement is available but not consistently published as a public retail-pharmacy reference. The AED is USD-pegged at 3.6725 AED per USD; the peg removes FX volatility. Price snapshot: 2026-05-31. Cost layers where the named-patient lane is invoked: ambient-temperature international logistics into the UAE (low to mid four-figure USD; ruxolitinib is a stable oral tablet), EDE permit fees (nominal), the dispensing haematology or BMT consultation and serial-CBC fees, and Reserve Meds concierge fee itemised separately. For Emirati nationals on Thiqa at SEHA facilities, ruxolitinib for registered indications is procured institutionally and OOP exposure is materially lower.

Funding and access barriers for Jakafi in the UAE

MF and PV affect predominantly older adults; steroid-refractory acute and chronic GVHD is a post-allogeneic-BMT complication. The UAE BMT case load at CCAD, SSMC, and Tawam provides the clinical context. Public-sector funding: for Emirati nationals, Thiqa-administered Daman insurance at daman.ae covers specialty haematology and BMT services at SEHA facilities including registered ruxolitinib; named-patient unregistered presentations require prior authorisation. Dubai-resident Emirati nationals on Salama or ENAYA receive comparable cover via DHA. MOHAP-administered free care for Emirati nationals applies in the Northern Emirates. For expatriates on mandatory health insurance, major insurers (Daman, Bupa Arabia, AXA Gulf, MetLife, Sukoon, Cigna Middle East, Allianz Worldwide Care, Mednet TPA, Nextcare TPA, NAS TPA) typically cover ruxolitinib for the registered indications on higher-tier policies with prior authorisation and documented step-therapy (for PV, hydroxyurea failure or intolerance; for MF, risk-stratification documentation; for GVHD, corticosteroid-refractoriness documentation). Novartis UAE patient-support programmes operate case-by-case for selected MPN and GVHD patients. The cold-chain step is not required for the oral tablet; the import-permit experience is procedurally straightforward.

Recent regulatory and access news for Jakafi

FDA continues post-marketing surveillance on long-term safety (serious infections, second primary malignancies, MACE) for the JAK-inhibitor class with periodic labelling updates at accessdata.fda.gov/scripts/cder/daf. Incyte and Novartis are pursuing further indication expansions including hydroxyurea-resistant PV combination studies. EMA's Jakavi EPAR at ema.europa.eu/medicines/Jakavi retains MF, PV, GVHD, and chronic GVHD indications. MOHAP transferred personal-use import permit service to EDE on 29 December 2025 per mohap.gov.ae/en/mte; UAE Jakafi personal-import applications now route through ede.gov.ae. No UAE-specific bulletin on Jakafi over the last 12 months as of 2026-05-31.

Where Reserve Meds fits in Jakafi cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDE, and we do not replace your dispensing pharmacy. For Jakafi specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into the UAE, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Jakafi case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDE application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

UAE haematology at Cleveland Clinic Abu Dhabi co-ordinates JAK inhibitor supply for myeloproliferative neoplasms with monthly complete blood count monitoring per the FDA label.

Next step

If your UAE physician has prescribed Jakafi and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Jakafi case Or message us on WhatsApp